Hoagizine: The New Perscription Sandwich From Pfizer

The extra-potent sandwich passed rigorous testing in both branches of the FDA in February. In clinical trials, 96 percent of patients who administered the sandwich orally experienced a deliciousness they described as "heightened," "intense," or even "overwhelming." In the same trial, only 16 percent of those who received placebo sandwiches reported experiencing high levels of deliciousness.

In preparation for Monday's announcement, Pfizer produced 800,000 units of the oral sandwich and distributed them to pharmacies nationwide. Additionally, Pfizer personnel sent out samples of Hoagizine and educated physicians on patient-screening procedures, treatment regimens, and serving suggestions.

[...]

Pfizer spokesman Abdul Johnson said Pfizer may soon offer an even more potent version of the sandwich, Hoagizine CM, which contains 10 grams of chipotle mayonnaise.